Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MarcoPolo Pharmaceuticals Announces a Positive Phase II-III Study in Partial Seizure Patients

Published: Thursday, March 20, 2014
Last Updated: Thursday, March 20, 2014
Bookmark and Share
Double-blind, placebo-controlled clinical study to evaluate the efficacy, safety and tolerability of VLB-01.

MarcoPolo Pharmaceuticals has announced results from interim analysis of the clinical study: “Double-blind, placebo-controlled clinical study to evaluate the efficacy, safety and tolerability of a fixed dose of VLB-01 as adjunctive therapy in patients with partial seizures (phase II-III)”.

VLB-01 has shown significant clinical and statistical results in phase II-III study in patients suffering from complex partial seizure secondary generalized or not which were not stabilized despite current antiepileptic treatment.

This was a randomized double blind placebo controlled study with 2 weeks titration and 12 weeks maintenance treatment. VLB-01 in dose 1500mg/day was very well tolerated and there were no safety issues reported from the trial.

The efficacy was clinically and statistically significant with median percent seizure reduction of about 60% for VLB-01, three times above the placebo (p<0.0001).

Similarly the response rate was about two times for VLB-01 compared to placebo. The rate of seizure-free patients ranged from 19 to 33% for VLB-01 compared to 10 to 17% for placebo.

VLB-01 belongs to a new pharmacological class: a Melatonin III (NRH: quinone oxidoreductase 2) receptor modulator of which VLB-01 is the first one tested in human.

Although the mode of action is not fully elucidated, pre-clinical evidence support that VLB-01 could have a disease modifying effect through neuroprotective proprieties.

“These are very promising results. Treatment resistant epilepsy is a devastating disease and despite intense research the unmet need remains very high. We are glad that VLB-01 could contribute to help patients with such severe condition. Our company is dedicated to pursue the effort and make VLB-01 available to patients at the earliest”, said Prof. Mondher Toumi, Chief Executive Officer.

Dr Alexander Bakhutashvili, Chief Medical Officer, added: “It is a great achievement with our second programme reaching a positive clinical proof of concept. We are committed to have this product approved in the Russian Federation for the end of this year or early next year. We expect the product to be a true break-through-therapy for those patients awaiting new therapy to help stabilizing their epileptic condition”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Open Source Seed Initiative – A Welcome Boost to Global Crop Breeding
A team of plant breeders, farmers, non-profit agencies, seed advocates, and policymakers have created the Open Source Seed Initiative.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Anthrax Proteins Might Help Treat Cancerous Tumors
Studies in mice reveal novel treatment regimen.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Key to Chronic Fatigue Syndrome is in Your Gut, Not Head
Researchers report they have identified biological markers of the disease in gut bacteria and inflammatory microbial agents in the blood.
HIV Structure Stabilized
Findings represent ‘big accomplishment’ in biomedical engineering and design.
Four Newly-Identified Genes Could Improve Rice
A Japanese research team have applied a method used in human genetic analysis to rice and rapidly discovered four new genes that are potentially significant for agriculture. These findings could influence crop breeding and help combat food shortages caused by a growing population.
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Antibodies To Dengue May Alter Course Of Zika Virus Infection
Scientists at Emory Vaccine Center, in collaboration with investigators from Thailand, have found that people infected with dengue virus develop antibodies that cross-react with Zika virus.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!